DAMORA THERAPEUTICS, INC. Marketable Securities, Unrealized Gain (Loss)
DAMORA THERAPEUTICS, INC. (DMRA) reported Marketable Securities, Unrealized Gain (Loss) of $34.00 thousand for the 9-month period ending 2024-09-30, per its 10-Q filed 2025-11-06.
Financial Statements › Income Statement › Other Income
us-gaap:MarketableSecuritiesUnrealizedGainLoss · last filed 2025-11-06
- DAMORA THERAPEUTICS, INC. marketable securities, unrealized gain (loss) for the quarter ending 2024-09-30 was $0.00, a 100.00% decline year-over-year.
- DAMORA THERAPEUTICS, INC. marketable securities, unrealized gain (loss) for the quarter ending 2024-06-30 was $2.00K, a 92.00% decline year-over-year.
- DAMORA THERAPEUTICS, INC. marketable securities, unrealized gain (loss) for the quarter ending 2024-03-31 was $32.00K, a 65.22% decline year-over-year.
- DAMORA THERAPEUTICS, INC. marketable securities, unrealized gain (loss) for the quarter ending 2023-12-31 was $58.00K, a 68.31% decline year-over-year.
- DAMORA THERAPEUTICS, INC. marketable securities, unrealized gain (loss) for fiscal 2023 was $231.00K.
- DAMORA THERAPEUTICS, INC. marketable securities, unrealized gain (loss) for fiscal 2022 was -$259.00K.
- DAMORA THERAPEUTICS, INC. marketable securities, unrealized gain (loss) for fiscal 2021 was -$77.00K.
| Period end | Marketable Securities, Unrealized Gain (Loss) 3 month | Marketable Securities, Unrealized Gain (Loss) 6 month | Marketable Securities, Unrealized Gain (Loss) 9 month | Marketable Securities, Unrealized Gain (Loss) 12 month |
|---|---|---|---|---|
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $2.00K derived: sum of 2 quarters · filed 2025-11-06 | $34.00K 10-Q · filed 2025-11-06 | $92.00K derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $2.00K 10-Q · filed 2025-08-05 | $34.00K 10-Q · filed 2025-08-05 | $92.00K derived: sum of 3 quarters · filed 2025-08-05 | $148.00K derived: sum of 4 quarters · filed 2025-08-05 |
| 2024-03-31 | $32.00K 10-Q · filed 2025-05-08 | $90.00K derived: sum of 2 quarters · filed 2025-05-08 | $146.00K derived: sum of 3 quarters · filed 2025-05-08 | $171.00K derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $58.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-19 | $114.00K derived: sum of 2 quarters · filed 2025-03-19 | $139.00K derived: sum of 3 quarters · filed 2025-03-19 | $231.00K 10-K · filed 2025-03-19 |
| 2023-09-30 | $56.00K 10-Q · filed 2024-11-01 | $81.00K derived: sum of 2 quarters · filed 2024-11-01 | $173.00K 10-Q · filed 2024-11-01 | $356.00K derived: sum of 4 quarters · filed 2024-11-01 |
| 2023-06-30 | $25.00K 10-Q · filed 2024-08-12 | $117.00K 10-Q · filed 2024-08-12 | $300.00K derived: sum of 3 quarters · filed 2024-08-12 | $218.00K derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | $92.00K 10-Q · filed 2024-04-29 | $275.00K derived: sum of 2 quarters · filed 2024-04-29 | $193.00K derived: sum of 3 quarters · filed 2024-04-29 | $38.00K derived: sum of 4 quarters · filed 2024-04-29 |
| 2022-12-31 | $183.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-08 | $101.00K derived: sum of 2 quarters · filed 2024-03-08 | -$54.00K derived: sum of 3 quarters · filed 2024-03-08 | -$259.00K 10-K · filed 2024-03-08 |
| 2022-09-30 | -$82.00K 10-Q · filed 2023-11-06 | -$237.00K derived: sum of 2 quarters · filed 2023-11-06 | -$442.00K 10-Q · filed 2023-11-06 | -$496.00K derived: sum of 4 quarters · filed 2023-11-06 |
| 2022-06-30 | -$155.00K 10-Q · filed 2023-07-31 | -$360.00K 10-Q · filed 2023-07-31 | -$414.00K derived: sum of 3 quarters · filed 2023-07-31 | -$380.00K derived: sum of 4 quarters · filed 2023-07-31 |
| 2022-03-31 | -$205.00K 10-Q · filed 2023-04-28 | -$259.00K derived: sum of 2 quarters · filed 2023-04-28 | -$225.00K derived: sum of 3 quarters · filed 2023-04-28 | -$202.00K derived: sum of 4 quarters · filed 2023-04-28 |
| 2021-12-31 | -$54.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | -$20.00K derived: sum of 2 quarters · filed 2023-03-09 | $3.00K derived: sum of 3 quarters · filed 2023-03-09 | -$77.00K 10-K · filed 2023-03-09 |
| 2021-09-30 | $34.00K 10-Q · filed 2022-11-08 | $57.00K derived: sum of 2 quarters · filed 2022-11-08 | -$23.00K 10-Q · filed 2022-11-08 | |
| 2021-06-30 | $23.00K 10-Q · filed 2022-07-29 | -$57.00K 10-Q · filed 2022-07-29 | ||
| 2021-03-31 | -$80.00K 10-Q · filed 2022-04-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |